Trius Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Trius Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

SAN DIEGO, Jan. 17, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc.
(Nasdaq:TSRX) today announced that it intends to offer and sell shares of its
common stock in an underwritten public offering. Citigroup and Leerink Swann
are acting as joint book-running managers and Baird is acting as a co-lead
manager. The offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or as to the
actual size or terms of the offering.

The securities described above are being offered by Trius pursuant to two
shelf registration statements previously filed with and declared effective by
the Securities and Exchange Commission (the "SEC") onSeptember 15, 2011 and
September 11, 2012. Preliminary prospectus supplements related to the offering
will be filed with theSECand will be available on the SEC's website at
http://www.sec.gov. Copies of the preliminary prospectus supplements and
accompanying prospectuses relating to these securities may also be obtained,
when available, from Citigroup, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, via telephone at 1-800-831-9146 or email at
batprospectusdept@citi.com or from Leerink Swann LLC, Attention: Syndicate
Department, One Federal Street, 37^th Floor, Boston, MA 02110, via telephone
at 1-800-808-7525 or email at Syndicate@Leerink.com. This press release shall
not constitute an offer to sell or the solicitation of an offer to buy these
securities, nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any
such state or other jurisdiction.

About Trius Therapeutics

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the
discovery and development of innovative antibiotics for serious infections.
The company's lead investigational drug, tedizolid phosphate, is a once daily,
IV and orally administered second generation oxazolidinone in Phase 3 clinical
development for the treatment of serious gram-positive infections, including
those caused by methicillin-resistant Staphylococcus aureus (MRSA). Trius has
partnered with Bayer HealthCare for the development and commercialization of
tedizolid phosphate outside of the U.S., Canada and the European Union. In
addition to the company's tedizolid phosphate clinical program, Trius has
initiated Investigational New Drug enabling studies for its Gyrase-B
development candidate with potent activity against Gram-negative bacterial
pathogens including multi-drug resistant strains of E. coli, Klebsiella,
Acinetobacter and Pseudomonas.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Because such statements are
subject to risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements. Such statements
include, but are not limited to, Trius' expectations regarding the completion,
timing and size of its proposed public offering. Among the factors that could
cause actual results to differ materially from those indicated in the
forward-looking statements are risks and uncertainties associated with market
conditions and the satisfaction of customary closing conditions related to the
proposed offering, as well as risks and uncertainties associated with Trius'
business and finances in general, and the other risks described in Trius'
Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, and in
the preliminary prospectus supplements related to the proposed offering to be
filed with the SEC. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Trius undertakes no
obligation to update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.

CONTACT: Public Relations Contact:
         Laura Kempke/Andrew Law at MSLGROUP
         trius@mslgroup.com
         781-684-0770
        
         Investor Relations Contact:
         Stefan Loren at Westwicke Partners, LLC
         sloren@westwicke.com
         443-213-0507
 
Press spacebar to pause and continue. Press esc to stop.